Secarna Pharmaceuticals publishes new preclinical data in The Journal of Immunology demonstrating potent therapeutic activity of LNAplus™ ASO targeting NLRP3 in highly debilitating autoinflammatory diseases

Written by Kirsten Ruehl on 6th July 2023. Posted in Client News.

• Previous
• Next